Cagrilintide

Cagrilintide API 

Cagrilintide is a long-acting, chemically synthesized amylin receptor agonist, developed as a novel treatment for obesity and weight-related metabolic disorders. It is designed to mimic the effects of human amylin, a hormone co-secreted with insulin by pancreatic β-cells, which plays a crucial role in regulating food intake, gastric emptying, and satiety.

Cagrilintide is being developed as a once-weekly injectable therapy, offering a highly promising solution for chronic weight management, especially when used in combination with GLP-1 receptor agonists such as Semaglutide.

Mechanism of Action

Cagrilintide exerts its therapeutic effects by binding to and activating amylin receptors, leading to:

• Appetite suppression

• Delayed gastric emptying, which prolongs the feeling of fullness

• Reduced calorie intake and increased satiety

This multimodal regulation of food intake makes it an ideal candidate for managing obesity and related cardiometabolic risks.

Research and Clinical Data

Cagrilintide has shown promising results in several clinical trials, including Phase 2 studies conducted by Novo Nordisk:

• When used alone, Cagrilintide leads to dose-dependent weight loss, with up to 10.8% body weight reduction over 26 weeks in obese individuals.

• When combined with Semaglutide, the weight loss effect is significantly enhanced—achieving greater reductions in body weight than either agent alone.

• It has shown favorable tolerability and a sustained safety profile, with most adverse events being mild gastrointestinal symptoms.

This combination approach is a key part of the next-generation anti-obesity drug pipeline, targeting multiple satiety pathways (amylin + GLP-1).

API Quality and Manufacturing

Our Cagrilintide API:

• Is produced through advanced solid-phase peptide synthesis (SPPS) with high purity and chemical stability

• Is designed for injectable formulation development

• Meets international pharmaceutical standards (ICH, GMP, FDA)

• Is available in pilot to commercial-scale production, suitable for clinical and industrial use

Therapeutic Potential

Cagrilintide represents a novel mechanism in weight management beyond GLP-1 monotherapy. Its complementary action profile makes it suitable for:

• Obesity and overweight patients (with or without diabetes)

• Combination therapy for enhanced weight loss

• Future development in metabolic syndrome and prediabetes